Marinomed has the vision to transform the lives of people suffering from diseases with limited or no treatment options in two key therapeutic areas: virology and immunology.
Coming from a clear OTC focus in the last 15 years, we have decided to expand the applications of iota-carrageenan in the field of viral infectious diseases and focus our Marinosolv-based pipeline on therapies for immune disorders as we aim to provide physicians and patients with powerful therapies to significantly improve the patients' quality of life.
MAM-1004-1/Budesolv is a nasal spray containing the corticosteroid budesonide solubilized with Marinomeds proprietary Marinosolv solubilization technology. Budesolv is intended to treat severe allergic rhinitis and has met all endpoints in a phase III clinical trial.
In addition to Budesolv, Marinomed has developed a dissolved fluticasone propionate formulation that has potential in the allergy area similar to Budesolv.
MAM-1003-1/Tacrosolv is a topically applied, anti-inflammatory and immunomodulating ophthalmic solution, containing Tacrolimus solubilized with Marinomeds proprietary Marinosolv solubilization technology.
In addition to the active ingredient xylometazoline, the nasal spray also contains Carrageenan. It supports xylometazoline in reducing the duration and intensity of symptoms associated with viral infections of the respiratory tract.
The Carragelose eye drops are intended to provide relief for dry eyes. Carragelose has excellent moistuirizing properties, an outstanding safety profile and is known for its virus-blocking effectiveness.
MAM-1001-1/Inhaleen is an inhalable formulation of Carragelose, which is a polymer extracted from red seaweed that forms a protective layer on mucosal surfaces. Carragelose has been well-established as broad-spectrum virus-blocking compound used in a marketed OTC product portfolio for the treatment of viral respiratory infections and has been shown to effectively inhibit a wide range of respiratory viruses.